EverGlade Insights

With the government fiscal year ending in a few short weeks and Covid continuing to impact the country, new government funding opportunities are plentiful for organizations supporting both the pandemic response and other areas of interest in the new Senate appropriations bill which will head for a vote by September 30, 2022. One of the […]

EverGlade Consulting (“EverGlade”), a Washington, D.C. based consulting firm, has successfully aided Detect, Inc. (“Detect”) in securing a contract with BARDA for the advanced development of a next-generation diagnostic device which is an over-the-counter home test that identifies and distinguishes between SARS-CoV-2 and influenza A and B nucleic acid using a single nasal swab.